Rofecoxib for rheumatoid arthritis

Garner, Sarah; Fidan, Dogan; Frankish, Ruth R; Judd, Maria; Towheed, Tanveer; Tugwell, Peter; Wells, George A.

doi:10.1002/14651858.cd003685.pub2

Cited by 38 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors (coxibs) are associated with an increased CV risk [78,79]. These observations may have important implications for the selection of agents used to treat patients with RA.…”

Section: Nonsteroidal Anti-inflammatory Drugsmentioning

confidence: 99%

Prevention of Stroke in Rheumatoid Arthritis

Dhillon

Liang

2015

Curr Treat Options Neurol

View full text Add to dashboard Cite

Recognizing that systemic inflammation is a major contributor to the increased risk of cardiovascular disease (CVD), including stroke, in rheumatoid arthritis (RA) serves as the basis for prevention strategies for cerebrovascular disease in RA. In addition to traditional cardiovascular risk factors, recognize that RA may be an independent risk factor for cerebrovascular accident (CVA). The risk of CVD should be assessed in each patient with RA, utilizing modified risk score calculators. Careful monitoring and control of systemic inflammation should be undertaken in conjunction with assessing each patient's CVD risk, acknowledging the benefits and risks of specific RA-directed therapies. Emphasis should be given to early and aggressive control of inflammation in RA patients, particularly those with seropositivity, increased inflammatory markers, long disease duration (>10 years), and/or extra-articular manifestations. In RA patients requiring glucocorticoid therapy, attempts should be made to use or wean to the minimal effective dose (preferably less than 7.5 mg/day). It should be recognized that both disease-modifying antirheumatic drugs (DMARDs), particularly methotrexate, and tumor necrosis factor (TNF)-alpha inhibitors partially mitigate the risk of CVD. In patients with inadequate control of inflammation with DMARDs, consideration should be given to switch to anti-TNF agents earlier in the disease process. Modifiable risk factors should be addressed as per guidelines for the general population. Active RA may be considered as a risk equivalent to diabetes mellitus when applying these guidelines. With regard to lipid management and use of statin therapy, further studies are required given the apparent "lipid paradox" in RA. Use of aspirin for primary prevention in RA has not been well studied; however, when aspirin is used for secondary prevention, one should recognize that concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) may decrease the antiplatelet effect. Given the cardiovascular risk associated with NSAIDs, the lowest possible dose for the shortest time should be used.

show abstract

Section: Nonsteroidal Anti-inflammatory Drugsmentioning

confidence: 99%

Prevention of Stroke in Rheumatoid Arthritis

Dhillon

Liang

2015

Curr Treat Options Neurol

View full text Add to dashboard Cite

show abstract

“…Two reviews were included from the Back group [6,7], seven from the MSK group [8][9][10][11][12][13][14], and one from the PaPaS group [15]. Reasons for review exclusion included: inappropriate/limited searches, generic/nonreview-specific search strategy, and subject matter out of the scope of authors' expertise (see Fig.…”

Section: Included Reviewsmentioning

confidence: 99%

“…Therefore, the reviews and results have been grouped into three intervention-based categories: pharmaceutical interventions (four reviews, [9,[11][12][13]), physical interventions (five reviews [6][7][8][9][10]14]), and psychosocial interventions (one review [15]). …”

Section: Sensitivity Specificity and Precision Of Simplified Searchmentioning

confidence: 99%

See 1 more Smart Citation

Simplified search strategies were effective in identifying clinical trials of pharmaceuticals and physical modalities

Day

Furlan

Irvin

et al. 2005

Journal of Clinical Epidemiology

View full text Add to dashboard Cite

“…One of dozens of medicines which have been withdrawn because of cardiotoxicity is rofecoxib, a non-steroidal antiinflamatory agent removed from the market due to the risk of myocardial infarction [98,99]. The agent has been initially prescribed to more than 80 million patients with arthritis and other conditions causing acute and chronic pain and its side effects should be unquestionably investigated in toxicity models relevant to human tissues [98,99].…”

Section: Human Esc and Cardiotoxicitymentioning

confidence: 99%

Stem Cells in Pharmaceutical Biotechnology

Zuba‐Surma

Józkowicz²,

Dulak³

2011

CPB

View full text Add to dashboard Cite

Multiple populations of stem cells have been indicated to potentially participate in regeneration of injured organs. Especially, embryonic stem cells (ESC) and recently inducible pluripotent stem cells (iPS) receive a marked attention from scientists and clinicians for regenerative medicine because of their high proliferative and differentiation capacities. Despite that ESC and iPS cells are expected to give rise into multiple regenerative applications when their side effects are overcame during appropriate preparation procedures, in fact their most recent application of human ESC may, however, reside in their use as a tool in drug development and disease modeling. This review focuses on the applications of stem cells in pharmaceutical biotechnology. We discuss possible relevance of pluripotent cell stem populations in developing physiological models for any human tissue cell type useful for pharmacological, metabolic and toxicity evaluation necessary in the earliest steps of drug development. The present models applied for preclinical drug testing consist of primary cells or immortalized cell lines that show limitations in terms of accessibility or relevance to their in vivo counterparts. The availability of renewable human cells with functional similarities to their in vivo counterparts is the first landmark for a new generation of cell-based assays. We discuss the approaches for using stem cells as valuable physiological targets of drug activity which may increase the strength of target validation and efficacy potentially resulting in introducing new safer remedies into clinical trials and the marketplace. Moreover, we discuss the possible applications of stem cells for elucidating mechanisms of disease pathogenesis. The knowledge about the mechanisms governing the development and progression of multitude disorders which would come from the cellular models established based on stem cells, may give rise to new therapeutical strategies for such diseases. All together, the applications of various cell types derived from patient specific pluripotent stem cells may lead to targeted drug and cellular therapies for certain individuals.

show abstract

Rofecoxib for rheumatoid arthritis

Cited by 38 publications

References 19 publications

Prevention of Stroke in Rheumatoid Arthritis

Prevention of Stroke in Rheumatoid Arthritis

Simplified search strategies were effective in identifying clinical trials of pharmaceuticals and physical modalities

Stem Cells in Pharmaceutical Biotechnology

Contact Info

Product

Resources

About